The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...
This blog is based on the analysis Frost RadarTM: Digital Biomanufacturing of Viral Vectors Vandana Iyer from the TechVision – Health & Wellness team. As the cell and gene therapy (CGT) market ...
Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...
CBM to provide Asimov's clonal HEK293 viral vector production platform to clients for preclinical and clinical manufacturing Clonal HEK293 suspension cell line is GMP-banked and qualified, ready for ...
Viral vectors are a key component of many advanced gene therapies and vaccines, but reliable, large-scale manufacturing remains a significant challenge. Continued innovation in vector design, cell ...
CBM to license Asimov's HEK293 viral vector production platform for use in preclinical and clinical manufacturing HEK293 cell line is GMP-banked and qualified, ready for immediate use Partnership ...
Boston, Dec. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Global Viral Vector Manufacturing Markets and Technologies Through 2030” is projected to grow from $6.3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback